Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany

Ulrike Leiter(University of Tübingen), Claus Garbe(University of Tübingen), Bernd Holleczek(Krebsregister Saarland), Thomas Eigentler(University Children's Hospital Tübingen), Alexander Katalinic(Independent Centre for Privacy Protection), Peter Martus(University of Tübingen), Ulrike Keim
Journal of Investigative Dermatology
May 6, 2017
10.1016/j.jid.2017.04.020
Cited by 231

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978